Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.88 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021791 | 0.91 | HTR1A (0.88) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL10052738 | 0.90 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL351932 | 0.89 | HTR1A (0.69) | HTR1ALMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10021795 | 0.88 | HTR1A (0.68) | HTR1A | |
| SCHEMBL351933 | 0.84 | HTR1A (0.81) | HTR1A | |
| SCHEMBL10021771 | 0.84 | HTR1A (0.62) | HTR1A | |
| SCHEMBL10021775 | 0.84 | HTR1A (0.67) | HTR1A | |
| SCHEMBL7722384 | 0.83 | HTR1A (0.73) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL7722387 | 0.83 | HTR1A (0.73) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL9036477 | 0.82 | HTR1A (0.71) | HTR1AADRA1DADRA1AADRA1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | HTR2A, HTR2C, HTR1A | HTR1A 3/4885ADRA1D 352/4885ADRA1A 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.